These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

194 related articles for article (PubMed ID: 23841743)

  • 1. Progressive multifocal leukoencephalopathy associated with ruxolitinib.
    Wathes R; Moule S; Milojkovic D
    N Engl J Med; 2013 Jul; 369(2):197-8. PubMed ID: 23841743
    [No Abstract]   [Full Text] [Related]  

  • 2. Pulmonary tuberculosis reactivation following ruxolitinib treatment in a patient with primary myelofibrosis.
    Chen YH; Lee CH; Pei SN
    Leuk Lymphoma; 2015 May; 56(5):1528-9. PubMed ID: 25213182
    [No Abstract]   [Full Text] [Related]  

  • 3. Long-term outcome of treatment with ruxolitinib in myelofibrosis.
    Tefferi A; Litzow MR; Pardanani A
    N Engl J Med; 2011 Oct; 365(15):1455-7. PubMed ID: 21995409
    [No Abstract]   [Full Text] [Related]  

  • 4. [Ruxolitinib prescription in myelofibrosis].
    Lemal R; Robin M; Ravinet A; Cacheux V; Guièze R; Bay JO
    Bull Cancer; 2013 Sep; 100(9):897-902. PubMed ID: 23985569
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Disseminated tuberculosis associated with ruxolitinib.
    Hopman RK; Lawrence SJ; Oh ST
    Leukemia; 2014 Aug; 28(8):1750-1. PubMed ID: 24625550
    [No Abstract]   [Full Text] [Related]  

  • 6. Pneumocystis jiroveci pneumonitis complicating ruxolitinib therapy.
    Lee SC; Feenstra J; Georghiou PR
    BMJ Case Rep; 2014 Jun; 2014():. PubMed ID: 24891492
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Hepatitis B virus reactivation associated with ruxolitinib.
    Shen CH; Hwang CE; Chen YY; Chen CC
    Ann Hematol; 2014 Jun; 93(6):1075-6. PubMed ID: 24173089
    [No Abstract]   [Full Text] [Related]  

  • 8. JAK inhibition with ruxolitinib as pretreatment for allogeneic stem cell transplantation in primary or post-ET/PV myelofibrosis.
    Stübig T; Alchalby H; Ditschkowski M; Wolf D; Wulf G; Zabelina T; Wolschke C; Ayuk F; Kröger N
    Leukemia; 2014 Aug; 28(8):1736-8. PubMed ID: 24569777
    [No Abstract]   [Full Text] [Related]  

  • 9. Fatal ruxolitinib-related JC virus meningitis.
    Ballesta B; González H; Martín V; Ballesta JJ
    J Neurovirol; 2017 Oct; 23(5):783-785. PubMed ID: 28791626
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Cytomegalovirus Retinitis in a Patient Who Received Ruxolitinib.
    von Hofsten J; Johnsson Forsberg M; Zetterberg M
    N Engl J Med; 2016 Jan; 374(3):296-7. PubMed ID: 26789901
    [No Abstract]   [Full Text] [Related]  

  • 11. Drug-associated skin lesions in a patient with myelofibrosis receiving ruxolitinib.
    Fournier JB; Cummings F; Cannella J; Breen C; Zhou L; Iwamoto S
    Dermatol Online J; 2014 Oct; 20(10):. PubMed ID: 25526003
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Ruxolitinib: the first agent approved for myelofibrosis.
    Verstovsek S
    Clin Adv Hematol Oncol; 2012 Feb; 10(2):111-3. PubMed ID: 22402352
    [No Abstract]   [Full Text] [Related]  

  • 13. Development of extramedullary sites of leukaemia during ruxolitinib therapy for myelofibrosis.
    Kremyanskaya M; Mascarenhas J; Rampal R; Hoffman R
    Br J Haematol; 2014 Oct; 167(1):144-6. PubMed ID: 24862179
    [No Abstract]   [Full Text] [Related]  

  • 14. Long-term Effects of the Janus Kinase 1/2 Inhibitor Ruxolitinib on Pulmonary Hypertension and the Cardiac Function in a Patient with Myelofibrosis.
    Miyawaki H; Kioka H; Sato K; Kurashige M; Ozawa T; Shibayama H; Hikoso S; Morii E; Yamauchi-Takihara K; Sakata Y
    Intern Med; 2020 Jan; 59(2):229-233. PubMed ID: 31534088
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Klebsiella pneumoniae primary liver abscess associated with ruxolitinib.
    Kusano Y; Terui Y; Ueda K; Hatake K
    Ann Hematol; 2016 Sep; 95(9):1561-2. PubMed ID: 27259987
    [No Abstract]   [Full Text] [Related]  

  • 16. Ruxolitinib (Jakafi) for myelofibrosis.
    Med Lett Drugs Ther; 2012 Apr; 54(1387):27-8. PubMed ID: 22469651
    [No Abstract]   [Full Text] [Related]  

  • 17. Ruxolitinib for myelofibrosis therapy: current context, pros and cons.
    Pardanani A
    Leukemia; 2012 Jul; 26(7):1449-51. PubMed ID: 22285996
    [No Abstract]   [Full Text] [Related]  

  • 18. Ruxolitinib in clinical practice for therapy of myelofibrosis: single USA center experience following Food and Drug Administration approval.
    Geyer H; Cannon K; Knight E; Fauble V; Camoriano J; Emanuel R; Tibes R; Mesa R
    Leuk Lymphoma; 2014 Jan; 55(1):195-7. PubMed ID: 23647081
    [No Abstract]   [Full Text] [Related]  

  • 19. Clinical and morphologic features in five post-polycythemic myelofibrosis patients treated with ruxolitinib.
    Iurlo A; Cattaneo D; Boiocchi L; Orofino N; Fermo E; Cortelezzi A; Gianelli U
    Ann Hematol; 2015 Oct; 94(10):1749-51. PubMed ID: 26082334
    [No Abstract]   [Full Text] [Related]  

  • 20. Ruxolitinib can mask symptoms and signs of necrotizing fasciitis.
    Landman GW; Arend SM; van Dissel JT
    J Infect; 2013 Mar; 66(3):296-7. PubMed ID: 23201967
    [No Abstract]   [Full Text] [Related]  

    [Next]    [New Search]
    of 10.